Skip to main content
Top
Published in: Journal of Translational Medicine 1/2008

Open Access 01-12-2008 | Commentary

Ex Vivo Metrics™, a preclinical tool in new drug development

Authors: C Gerald Curtis, Kevin Bilyard, Hugo Stephenson

Published in: Journal of Translational Medicine | Issue 1/2008

Login to get access

Abstract

Among the challenges facing translational medicine today is the need for greater productivity and safety during the drug development process. To meet this need, practitioners of translational medicine are developing new technologies that can facilitate decision making during the early stages of drug discovery and clinical development. Ex Vivo Metrics™ is an emerging technology that addresses this need by using intact human organs ethically donated for research. After hypothermic storage, the organs are reanimated by blood perfusion, providing physiologically and biochemically stable preparations. In terms of emulating human exposure to drugs, Ex Vivo Metrics is the closest biological system available for clinical trials. Early application of this tool for evaluating drug targeting, efficacy, and toxicity could result in better selection among promising drug candidates, greater drug productivity, and increased safety.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wood AJJ: A proposal for radical change in the drug-approval process. N Engl J Med. 2006, 355: 618-623. 10.1056/NEJMsb055203.CrossRefPubMed Wood AJJ: A proposal for radical change in the drug-approval process. N Engl J Med. 2006, 355: 618-623. 10.1056/NEJMsb055203.CrossRefPubMed
2.
go back to reference Mervis J: Productivity counts – but the definition is key. Science. 2005, 309: 726-727. 10.1126/science.309.5735.726.CrossRefPubMed Mervis J: Productivity counts – but the definition is key. Science. 2005, 309: 726-727. 10.1126/science.309.5735.726.CrossRefPubMed
3.
go back to reference Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006, 355: 1018-1028. 10.1056/NEJMoa063842.CrossRefPubMed Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006, 355: 1018-1028. 10.1056/NEJMoa063842.CrossRefPubMed
4.
go back to reference Littman BH, Di Mario L, Plebani M, Marincola FM: What's next in translational medicine?. Clin Sci (Lond). 2007, 112: 217-227.CrossRef Littman BH, Di Mario L, Plebani M, Marincola FM: What's next in translational medicine?. Clin Sci (Lond). 2007, 112: 217-227.CrossRef
5.
go back to reference Curtis CG, Chien B, Bar-Or D, Ramu K: Organ perfusion and mass spectrometry: a timely merger for drug development. Curr Top Med Chem. 2002, 2: 77-86. 10.2174/1568026023394623.CrossRefPubMed Curtis CG, Chien B, Bar-Or D, Ramu K: Organ perfusion and mass spectrometry: a timely merger for drug development. Curr Top Med Chem. 2002, 2: 77-86. 10.2174/1568026023394623.CrossRefPubMed
Metadata
Title
Ex Vivo Metrics™, a preclinical tool in new drug development
Authors
C Gerald Curtis
Kevin Bilyard
Hugo Stephenson
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2008
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-6-5

Other articles of this Issue 1/2008

Journal of Translational Medicine 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.